India: CCI Imposes Penalties On The Chemists' Associations In State Of Gujarat And Three Pharma Companies For Indulging In Practice Of "No Objection Certificate" Before Appointment Of Stockists

Last Updated: 8 January 2019

Article by MM Sharma, Head Competition Law & Policy Practice, Vaish Associates, Advocates, New Delhi, India

The Competition Commission of India ("CCI") by way of an order dated 12 July 2018 has imposed penalty on the Federation of Gujarat State Chemists and Druggists Association, Amdavad Chemist Association , Surat Chemists and Druggists Association and the Chemists and Druggists Association of Baroda (collectively 'chemists and druggist associations') as well as three pharmaceutical companies namely Glenmark Pharmaceutical Limited (and its C & F agent), Hetero Healthcare Ltd and Divine Saviour (collectively 'pharmaceutical companies') for violating provisions of the Competition Act, 2002 ('Act'). Penalties were also imposed on the individual office bearers of the chemists and druggists associations and managing directors and concerned employees of the three pharma companies.

The investigation by the CCI was directed on allegations made by the Informants viz. Alis Medical Agency, M/s Stockwell pharma, M/s Apna Dawa Bazaar and Reliance Medical Agency against , not only the chemists & druggists associations but also against a large number of leading pharma companies and their Carrying & Forwarding agents (C&F Agents) alleging that the pharmaceutical companies and their C&F agents were mandating the requirement of a non-objection certificate (NOC) from the chemists and druggist associations prior to the appointment of their stockists.

During the detailed investigation , the DG, did not find any evidence of the majority of pharma companies and their C&F agents indulging in the practice of obtaining NOC before appointing new stockists except (Glenmark Pharmaceutical Ltd ("Glenmark") , Cadilla Healthcare Ltd.("Cadilla") ( and their C&F agents) and Hetero Healthcare Ltd and Divine Saviour. The finding against the above named four companies was based on the documentary evidence found from their records and (in the case of Glenmark and its C&F agent) the transcript of tape recorded telephonic conversation , recorded by one of the Informant with the C&F agent of Glenmark . The explanation regarding the incriminating documentary evidence and the transcript of the tape recording , given by the four pharma companies and their C&F agents  was not accepted by the DG .

The findings of the DG were challenged by the chemists & druggists association and the four pharma companies and their C&F agents by detailed written objections before CCI as well as during oral arguments held before CCI . It was emphasized that multiple cases have been filed by the same set of persons, namely Shri Nayan Raval and Shri Dahyabhai Patel, alleging the same facts, with ill-motives because of the political rivalry between competing factions of the chemists and druggists associations based in the State of Gujarat . It was stressed that the Informants had used the Information to settle scores with their political rivals and had fabricated evidence such as tape recording the telephonic conversations to rope in the pharma companies to put pressure on them to concede to their unjust demands and had tried to mislead the CCI .

One of the pharma companies, Cadilla , even challenged the initial prima facie order of the CCI under section 26(1) of the Act on the above grounds and also the summoning of the Managing Director of Cadilla by CCI after the DG investigation without adjudicating the role of the company under section 48(1) of the Act , before the Delhi High Court by way of a writ petition, which was dismissed by the Single Bench of the High Court but the letter patent appeal (LPA) filed by Cadilla before the Division Bench  is pending  before the High Court.

Following the conclusion of the oral hearings held during the inquiry, the CCI rejected the objections taken by the Opposite Parties including the pharma companies and held  that the chemists and druggist associations, were indulging in the practice of NOC prior to the appointment of stockists, which has the effect of limiting and controlling of the supply of drugs in the market, in violation of Section 3(3) of the Act. Further, it was observed that instead of desisting from such activity, these associations are mandating the NOC requirement, either verbally (in order to avoid any documentary evidence/proof) or under camouflaged congratulatory/intimation letters.

The CCI also held that the three pharmaceutical companies and their C&F agents, without any resistance, cooperate with such associations to implement their anti-competitive decisions, thereby becoming equally complicit in the anti-competitive effect of such practice. Instead of approaching the CCI, these pharmaceutical companies cooperate with the NOC requirement of the associations, thus becoming perpetrators of such anti-competitive practice which was in violation of Section 3(1) of the Act. The order against Cadilla was reserved due to pendency of the LPA before the Delhi High Court.

The CCI imposed a monetary penalty of INR 9,68,651/- , INR 1,11,278/- , INR 1,09,413/- and INR 61,232/- calculated at the rate of 10 % of the average income of each of the chemists and druggist associations under the provisions of Section 27 of the Act.

Penalty on the pharmaceutical companies were imposed at the rate of 1% of the their average income based on their financial statements of the three years which amounts to 4,500 Lakhs for Glemark, INR 0.20 lakhs on Glenmark's C & F Agent,  INR 228.92 lakhs on Hetero Healthcare Ltd and INR 5.61 lakhs on Divine Savior Pvt. Ltd.

In addition, monetary penalties were imposed on the office bearers of the chemists and druggist association, and the officials of the pharmaceutical companies at the rate of 1% of their incomes, respectively. Furthermore, the chemists and druggist associations, the pharmaceutical companies and their office bearers/officials were directed to cease and desist from indulging in the practice of mandating NOC prior to stockiest appointment.

Comment: This case is important because, firstly,  it was for the first time a series of complaints were filed by some stockists against such large number of leading pharma companies pan India , secondly, the CCI has ignored the apparent ill- motive of the Informantto use the forum of the CCI to settle political scores with rival factions in the trade associations and thirdly , the CCI has arrived on its findings of violation of section 3(1) of the Act against the pharma companies , without going into the real issue whether the so called practice of NOC ( whose existence was also not conclusively proved and was rather presumed by the DG on the basis of few isolated instances found in the internal records of the four pharma companies) was causing any appreciable adverse effect on competition or not .In my view , the CCI also did not visualize that the pharma companies are actually victims and cannot be perpetrators of the practice of NOC . The decision raises many substantive legal issues which will be settled only after the decisions in the appeals to be filed by all the Opposite Parties.   

Specific Questions relating to this article should be addressed directly to the author.

© 2018, Vaish Associates Advocates,
All rights reserved
Advocates, 1st & 11th Floors, Mohan Dev Building 13, Tolstoy Marg New Delhi-110001 (India).

The content of this article is intended to provide a general guide to the subject matter. Specialist professional advice should be sought about your specific circumstances. The views expressed in this article are solely of the authors of this article.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions